OA
FOLD

Omega Advisors’s Amicus Therapeutics FOLD Stock Holding History

Omega Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-374,000
Closed -$5.63M – 90
2018
Q1 		$5.63M Buy
374,000
+274,000
+274% +$4.17M 0.21% 58
2017
Q4 		$1.44M Buy
+100,000
New +$1.37M 0.05% 64

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omega Advisors's FOLD Position: Q2 2018 in Review

Omega Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2018, closing a stake of 374,000 shares — an estimated $5.63M sold.

Omega Advisors first reported a position in FOLD in Q4 2017 and held it in 2 quarters. The position peaked at $5.63M in Q1 2018. 200 funds tracked by Wall St. Rank hold FOLD as of Q2 2018.

  • Omega Advisors reported no remaining Amicus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Omega Advisors sold 374,000 Amicus Therapeutics shares in Q2 2018, an estimated $5.63M.
  • Omega Advisors first reported a position in Amicus Therapeutics in Q4 2017 and held it in 2 quarters.
  • Omega Advisors's Amicus Therapeutics position peaked at $5.63M in Q1 2018.
  • 200 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2018.

Based on Omega Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.